Corteva (NYSE:CTVA) Sets New 1-Year High – Here’s Why

Corteva, Inc. (NYSE:CTVA) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $89.75 and last traded at $88.98, with a volume of 5697592 shares trading hands. The stock had previously closed at $87.58.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Quarterly earnings exceeded expectations: Corteva reported second-quarter EPS of $2.30, above the $2.24 consensus estimate and up from $2.20 a year earlier. Corteva Q2 Earnings Beat Estimates
• Positive Sentiment: Full-year outlook was raised: Management increased its 2026 EPS guidance to $3.60-$3.80, reflecting strong first-half performance, cost controls and growth from strategic platforms. The midpoint is broadly consistent with analyst expectations. Corteva Delivers Strong First Half and Raises Outlook
• Positive Sentiment: Growth initiatives remain supportive: Demand for newer seed germplasm, trait technologies and crop-protection products, along with licensing growth and operational improvements, helped offset competitive pricing pressure. Corteva also remains on schedule for the planned October 1 Vylor spin-off. Why Corteva’s Seed and Crop Protection Engines Matter
• Neutral Sentiment: Separation could reshape the investment story: Corteva’s innovation pipeline, including crop-protection products and royalty opportunities, may support future growth after the planned business split, although the benefits will depend on execution. Corteva’s Innovation Pipeline
• Negative Sentiment: Revenue missed expectations: Second-quarter revenue was $6.38 billion, below the $6.60 billion analyst estimate, and declined 1.2% year over year. Competitive pricing remains a concern. Corteva Earnings Press Release
• Negative Sentiment: Valuation and execution risks are elevated: After a powerful rally, CTVA trades near its 52-week high at a premium earnings multiple. Investors may remain cautious about separation costs, execution risk and whether growth can justify the valuation. Is CTVA Stock Worth Buying After Its Rally?

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CTVA. BNP Paribas Exane upped their target price on Corteva from $74.00 to $77.00 in a research report on Wednesday, May 6th. The Goldman Sachs Group lifted their price target on Corteva from $88.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Jefferies Financial Group boosted their price target on Corteva from $95.00 to $97.00 in a research note on Thursday, May 7th. Weiss Ratings upgraded Corteva from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, May 7th. Finally, Morgan Stanley raised their price objective on shares of Corteva from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.19.

Corteva Trading Down 1.2%

The company has a fifty day simple moving average of $82.16 and a two-hundred day simple moving average of $79.55. The company has a market capitalization of $59.79 billion, a P/E ratio of 52.58, a price-to-earnings-growth ratio of 2.74 and a beta of 0.56. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.47 and a quick ratio of 1.03.

Corteva (NYSE:CTVA) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.06. The company had revenue of $6.38 billion during the quarter, compared to the consensus estimate of $6.60 billion. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The firm’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.20 EPS. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. On average, analysts forecast that Corteva, Inc. will post 3.76 earnings per share for the current fiscal year.

Corteva Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be issued a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.8%. The ex-dividend date is Tuesday, September 1st. Corteva’s payout ratio is 42.35%.

Hedge Funds Weigh In On Corteva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Drummond Knight Asset Management Pty Ltd acquired a new position in Corteva during the 4th quarter worth $25,713,000. Arbejdsmarkedets Tillaegspension acquired a new stake in shares of Corteva in the fourth quarter valued at about $23,679,000. Leonteq Securities AG acquired a new stake in shares of Corteva in the fourth quarter valued at about $2,350,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Corteva by 23.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,075 shares of the company’s stock worth $7,378,000 after purchasing an additional 20,957 shares during the period. Finally, Brandes Investment Partners LP increased its stake in shares of Corteva by 1.1% in the fourth quarter. Brandes Investment Partners LP now owns 2,312,515 shares of the company’s stock worth $155,009,000 after purchasing an additional 24,985 shares during the period. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.